Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure

  title={Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure},
  author={Yan-ling Jiang and Oliver N. Lin and Sidhartha R. Sinha},
  journal={Digestive Diseases and Sciences},
BackgroundPrescribing information for tumor necrosis factor alpha (TNFα) inhibitors, a mainstay of treatment for moderate to severe inflammatory bowel disease (IBD), instructs cautious use in those with heart failure (HF). However, the limited data behind these warnings are inconclusive and should be weighed against mounting evidence demonstrating worse cardiac outcomes in active IBD.AimsTo assess whether TNFα inhibitor use is reduced in patients with IBD and HF by analyzing physician practice… 
The Exopolysaccharide Produced by Lactobacillus paracasei IJH-SONE68 Prevents and Ameliorates Inflammatory Responses in DSS–Induced Ulcerative Colitis
It is concluded that the IJH-SONE68-derived EPS is a promising lead material for the development of drugs useful in treating inflammatory diseases such as UC.
Systematic review and meta-analysis of drug induced liver injury secondary to biologic medications in inflammatory bowel disease
Ulcerative colitis is almost certainly an autoimmune disease initiated by an in lammatory disease, but it seems to occur in genetically disposed people in response to environmental factors.
Protective Role of Coxsackie-Adenovirus Receptor in the Pathogenesis of Inflammatory Bowel Diseases
It is found that CAR levels in human colon cell lines are significantly downregulated under the treatment of tumor necrosis factor-alpha and may serve as a therapeutic target for the diagnosis and treatment of IBD.


Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases.
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist
Evidence is found that TNF antagonists can exacerbate heart failure or promote new-onset heart failure and that patients younger than 50 years of age are relatively unlikely to develop heart failure.
Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.
Although there was an increased relative risk of incident, HF that was not statistically significant among those exposed to TNF-alpha antagonists compared to those unexposed, larger cohorts are needed to provide more precise risk estimates and permit adjustment for potential confounding.
Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease.
TNF-alpha secreting cells are increased in the mucosa of inflamed intestine, regardless of pathogenesis, and higher levels are seen in patients with IBD than in UC, probably reflecting the extensive T-cell activation in Crohn's disease.
Inflammatory Bowel Disease Is Associated With an Increased Risk of Hospitalization for Heart Failure: A Danish Nationwide Cohort Study
In a nationwide cohort, IBD was associated with an increased risk of hospitalization for HF, and this risk was strongly correlated to periods of active disease.
Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease.
Increased secretion of TNF alpha and interleukin 1beta were predictive for acute relapses within the next year and may identify patients who would benefit from anti-inflammatory remission maintenance in Crohn's disease.